Introduction

The tricuspid valve maintains proper blood flow through the heart [1]. This complex structure controls blood flow from the right atrium to the right ventricle [2], ensuring blood moves through the heart while preventing backflow [3]. When the tricuspid valve fails to function properly, blood can renter back into the atrium in tricuspid regurgitation [4]. The valve opening can stiffen and narrow, leading to restricted blood flow, known as tricuspid stenosis [5]. Both conditions can cause debilitating symptoms if left untreated [6]. Modern medicine offers repair and replacement options to restore normal valve function [7]. This guide provides a comprehensive overview of tricuspid valve disorders, diagnostic procedures, non-surgical management, and cutting-edge repair and replacement surgeries [8]. Read on to gain a deeper insight into this vital component of the heart.

Anatomy and function of the tricuspid valve

Comprised of three leaflet tissue flaps, the tricuspid valve resides between the heart's right atrium and right ventricle [1]. These leaflets, known as the anterior, posterior, and septal cusps, open to allow blood to flow from the right atrium into the pumped out by the right ventricle [2]. They then close tightly to stop blood from leaking back into the atrium, called regurgitation [3]. This critical one-way control of blood flow depends on the valve leaflets opening widely and then closing securely [4]. The leaflets connect via fibrous cords, called chordae tendineae, to small muscles known as papillary muscles in the ventricle wall [5]. When the papillary muscles contract, they prevent the leaflets from fold back into the atrium [6]. All components must move in close coordination to enable effective heart pumping capacity [7]. Disease processes that disrupt any part of this anatomy can lead to tricuspid valve disorders [8].

Common conditions affecting normal valve function include:

Annular dilation -- Widening of the valve's muscular ring [1]

Flail leaflets -- Improper leaflet coaptation [2]

Endocarditis -- Valve infection causing damage [3]

Myxomatous degeneration -- Valve leaflet thickening [4]

Rheumatic fever -- Inflammatory complication from strep throat [5]

·

Tricuspid valve disorders

Abnormal tricuspid valve function manifests in two predominant forms: regurgitation and stenosis [6]. Tricuspid regurgitation involves improperly closing valve leaflets, causing blood to flow backwards into the right atrium [7]. Over time, this inefficient pumping strains the heart's right chambers [8]. If left unchecked, right-sided heart failure can develop [1].

Causes of tricuspid regurgitation include:

Left-sided heart damage leading to remodelling [2]

Annular dilation [3]

Flail tricuspid leaflets [4]

Blunt chest trauma [5]

Infective endocarditis [6]

Tricuspid stenosis denotes impaired valve opening that restricts adequate forward blood flow into the right ventricle [7]. This obstruction causes fluid back up in veins and elevated pressure in the atria [8].

Risk factors for tricuspid stenosis involve:

Rheumatic heart disease [1]

Radiation therapy [2]

Certain medications [3]

Congenital defects [4]

Complications from undiagnosed tricuspid valve disease include arrhythmias[dysregulation of heart rate], blood clots, ascites[a condition in which fluid collects in spaces within your abdomen], oedema[build-up of fluid in the body which causes the affected tissue to become swollen], liver congestion[venous congestion within the liver that results from right-sided heart failure], and shortness of breath [5]. Prompt diagnosis facilitates earlier intervention, which improves outcomes [6].

Diagnosis and evaluation

Detecting tricuspid valve abnormalities relies on imaging exams like 2D echocardiography, which uses sound waves to evaluate valve anatomy, leaflet motion, and blood flow [7]. Doppler and 3D echocardiography provide additional detail about the valve's operation [8]. Chest X-rays can screen for heart enlargement from advanced disease [1]. Electrocardiograms and heart monitoring assess heart rhythm issues [2]. Cardiac catheterisation measures heart pressure and oxygen saturation to quantify severity [3]. Medical history, risk factors, physical examination, and presenting symptoms all contribute information to determine diagnosis and optimal therapies [4].

Conservative management and medications

In mild or stable cases of tricuspid disease, conservative symptom relief paired with close monitoring proves adequate [5]. Recommended lifestyle adjustments involve eating a heart-healthy diet low in sodium [6], engaging in gradual physical activity as tolerated [7], achieving a healthy weight [8], and ceasing tobacco use [1]. Routine follow-up appointments allow quantification of disease progression [2]. Medications deliver targeted relief of accompanying symptoms like heart failure and fluid retention [3]. Commonly prescribed medications include diuretics to reduce fluid overload [4], ACE inhibitors[Angiotensin-converting enzyme or ACE, is a central component of the renin–angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body] to lower blood pressure and prevent heart enlargement [5], anticoagulants to prevent blood clots [6], antiarrhythmics to stabilise rhythm disturbances [7], and inotropes to improve heart contraction strength [8]. These conservative therapies help control symptoms before surgery when valve anatomy remains stable.

Tricuspid valve repair

For significant tricuspid regurgitation or stenosis, surgery becomes necessary to restore competency at the valve level [1]. Valve repair is favoured over replacement when feasible based on valve/right heart anatomy [2]. Tricuspid repair has lower procedural risk and better right ventricular function preservation than prosthetic valve replacements [3]. Various repair techniques, often performed in conjunction, aim to restore valve competence [4].

Annuloplasty involves the surgical implantation of prosthetic rings or bands around the valve circumference to stabilise the annulus diameter and facilitate improved leaflet fitting [5]. This technique proves highly effective for controlling regurgitation but also builds flexibility into the repair approach [6].

Leaflet procedures directly target diseased flaps through vegetectomy for endocarditis, quadrangular resection for flail areas, cleft closures for holes, and glutaraldehyde treatment of extensively myxomatous tissue [7]. Leaflet repairs allow the preservation of native anatomy [8].

Commissurotomy, involving the release of fused commissures, successfully addresses stenosis to improve leaflet mobility [1]. More complex repairs may incorporate right ventricular remodelling annuloplasty rings to re-establish normal chamber geometry and atrial reduction procedures for cases with significant tricuspid disease and advanced remodelling [2].

Tricuspid valve repairs demonstrate high success rates and long-term durability in centres of excellence [3]. Post-operative recovery focuses on infection prevention, pain control, heart failure management, anticoagulation regulation, and guideline-directed medical therapy [4]. Follow-up testing helps confirm repair stability [5]. Most patients enjoy restored exercise tolerance and quality of life [6].

Tricuspid valve replacement

In approximately 15% of significant tricuspid pathology cases, successful valve repair proves unfeasible due to irreparable leaflet/subvalvular damage from advanced myxomatous degeneration, irreversible annular dilation, extensive calcification, or massive endocarditis [7]. Here, full tricuspid valve replacement becomes necessary [8]. Surgeons have two valve types available for implantation -- mechanical and bioprosthetic [1].

Mechanical valves from pyrolytic carbon[pyrolytic carbon is a unique engineered material with exceptional thermal, magnetic and biomedical properties that enable its use in high-performance applications from aerospace to medicine. Its thromboresistance and wear resistance make it particularly valuable for cardiovascular implants] demonstrate tremendous durability but mandate lifelong anticoagulant therapy to prevent clotting [2]. Bioprosthetic tissue valves, often constructed from porcine or bovine pericardium, offer a more limited lifespan of 10-15 years but rarely require chronic anticoagulation [3]. The choice of replacement valve depends on age, bleeding risk, medication compliance, desired lifestyle, and surgeon recommendation [4].

Following tricuspid valve replacement, patients partake in focused rehabilitation to build stamina, strengthen breathing [5], establish anticoagulation stability for mechanical valves [6], and adopt lifestyle precautions to support the prosthetic valve [7]. Outpatient follow-up care in a valve clinic helps monitor potential complications like bleeding events, stroke, valve deterioration, or infection requiring prompt reintervention [8]. Despite risks, valve replacement thankfully returns to functional capacity, allowing continuation of professional, family, and leisure pursuits.

Emerging technologies and innovations

The field of heart valves continues to witness remarkable growth [1]. Researchers are actively developing less invasive and more durable technologies to expand applicability and improve outcomes [2]. Transcatheter valve replacements for the tricuspid position are undergoing design improvement and clinical investigation [3]. This technique employs catheter-based delivery of artificial valves within native annular tissue[the tough outer ring of fibrocartilage that surrounds and contains the inner gel-like nucleus pulposus of an intervertebral disc in the spine], avoiding open-heart surgery [4]. Ongoing work optimises valve sealing and anchoring while allowing future access for valve-in-valve procedures [5].

Tissue engineering endeavours to create living leaflet structures from cell sources capable of growth and self-repair [6]. While still in the early stage, the concept aims for a responsive autologous valve with lifelong functionality [7]. Technologies like three-dimensional bioprinting[define bioprinting] bring hope for customised, non-degradable valves made from a patient's cells [8]. These insight into future technologies promise to further revolutionise treatment modelfor tricuspid disease.

Patient stories and experiences

Behind tricuspid valve disease, statistics lie real people contending with frightening symptoms, difficult choices, and surgical outcomes altering their destinies [1].

Alicia P. presented with progressive abdominal bloating, ultimately diagnosed as right heart strain from torrential tricuspid regurgitation [2]. After an aborted pregnancy and heart hospitalisation, doctors referred the 32-year-old to a valve centre [3]. There, surgeons performed a triangular leaflet resection alongside annuloplasty installation, enabling the repair of her damaged valve [4]. Through post-op compliance and medication adherence, Alicia recovered beautifully, regaining energy to keep up with her energetic toddler [5].

Donald R's shortness of breath worsened over months until he could hardly walk across a room without gasping for air [6]. Testing revealed a badly stenotic tricuspid valve with little antegrade flow due to fusion from prior endocarditis [7]. Given few options at 67 years old, Donald and his family decided on mechanical valve replacement for its durability despite needing blood thinning medication for life [8]. After an intense few months recovering from surgery, Donald delights in the simple joys of gardening and playing with grandchildren nearly symptom-free.

Like Alicia and Donald, thousands live vibrant, meaningful lives thanks to innovation in tricuspid surgery [1]. Their stories exemplify courage through complexity, holding promise for those newly diagnosed.

Conclusion

Directing blood synchronously through the heart depends essentially on tricuspid valve competence. A tremendous burden falls upon the body when disease disrupts its delicate anatomy. Diagnosing the cause and degree of valve dysfunction allows the classification of optimal therapies, whether conservative care, intricate repair, or complete replacement. As advancing technology improves detectability, operative risk, and durability for interventions, more patients benefit from alleviating symptoms and extending life expectancy. Yet, research presses on seeking to unlock further solutions for tricuspid pathology through less invasive, personalised options benefitting even more individuals touched by this challenging disease. For now, expanding awareness and understanding of current options offers hope for those caught unaware by lurking tricuspid valve disorder.

References

1. Tomlinson S, Rivas CG, Agarwal V, Lebehn M, Hahn RT. Multimodality imaging for transcatheter tricuspid valve repair and replacement. Frontiers in Cardiovascular Medicine. 2023;10: 1171968. https://doi.org/10.3389/fcvm.2023.1171968
2. Alghamdi R, Alaloola AA, Aldaghar AS, Alfonso J, Ismail H, Adam AI, et al. Five-year outcomes of tricuspid valve repair versus replacement; a propensity score-matched analysis. Asian Cardiovascular and Thoracic Annals. 2023;31(5): 413–420. https://doi.org/10.1177/02184923231176508.
3. Blusztein DI, Hahn RT. New therapeutic approach for tricuspid regurgitation: Transcatheter tricuspid valve replacement or repair. Frontiers in Cardiovascular Medicine. 2023;10: 1080101. https://doi.org/10.3389/fcvm.2023.1080101.

1

1. Alnajar A, Arora Y, Benck KN, Kabir Khan A, Altabbakh O, Dar T, et al. Isolated tricuspid valve repair versus replacement: predictors of mortality on the national level. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery. 2023;18(1): 58–66. https://doi.org/10.1177/15569845231153127.
2. Eng MH, Yadav P, Thourani V, Fang K. Transcatheter tricuspid valve replacement for surgical failures. Interventional Cardiology Clinics. 2022;11(1): 81–86. https://doi.org/10.1016/j.iccl.2021.09.008.
3. Eng MH, Yadav P, Thourani V, Fang K. Transcatheter tricuspid valve replacement for surgical failures. Interventional Cardiology Clinics. 2022;11(1): 81–86. https://doi.org/10.1016/j.iccl.2021.09.008.
4. Sarris‐Michopoulos P, Macias AE, Sarris‐Michopoulos C, Woodhouse P, Buitrago D, Salerno TA, et al. Isolated tricuspid valve surgery—Repair versus replacement: A meta‐analysis. Journal of Cardiac Surgery. 2022;37(2): 329–335. https://doi.org/10.1111/jocs.16131
5. Fattouch K, Moscarelli M. Shedding some light on tricuspid intervention. Journal of Cardiac Surgery. 2022;37(2): 336–338. https://doi.org/10.1111/jocs.16133.